Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4 results about "Bile acid sequestrant" patented technology

The bile acid sequestrants are a group of resins used to bind certain components of bile in the gastrointestinal tract. They disrupt the enterohepatic circulation of bile acids by combining with bile constituents and preventing their reabsorption from the gut. In general, they are classified as hypolipidemic agents, although they may be used for purposes other than lowering cholesterol. They are used in the treatment of chronic diarrhea due to bile acid malabsorption.

Compositions and methods for treating bile acid malabsorption

PendingAU2025215211A1ColitisBile acid sequestrant
Pharmaceutical compositions comprising bile acid sequestrants, their use in treating bile acid malabsorption, and associated conditions such as bile acid diarrhea and colitis are described herein. Methods for treating bile acid malabsorption and associated conditions are also described.
Owner:COSMO TECHNOLOGIES LTD

Therapies with PPAR agonists and FGFR3 inhibitors

PCT designated stageWO2026143225A1Activating receptorsBile acid biosynthesis
Provided are methods of treating subjects in need of an anti-fibroblast growth factor receptor 3 (anti-FGFR3) therapy. The methods comprise administering to the subjects a therapeutically effective amount of a peroxisome proliferator-activated receptor (PPAR) alpha agonist in combination with the anti-FGFR3 therapy. The methods can comprise administering to the subject a therapeutically effective amount of PPAR alpha agonist and a bile acid sequestrant. Also provided are compositions comprising an FGFR3 inhibitor, a PPAR alpha agonist, and, optionally, a bile acid sequestrant. The methods attenuate the dysregulation of bile acid biosynthesis caused by FGFR3 inhibition with anti-FGFR3 therapies. The methods reduce the severity and / or incidence of adverse events associated with anti-FGFR3 therapies.
Owner:TYRA BIOSCIENCES INC

Ammonium salt polymer, method for preparing same, and use thereof as bile acid chelating agent

An ammonium salt polymer, a method for preparing same, and use thereof as a bile acid chelating agent. The ammonium salt polymer is obtained by polymerizing a monomer of Formula (I) and a monomer of Formula (II), wherein m, n, p, q, and r are each independently selected from 1, 2 or 3. The ammonium salt polymer contains monovalent, divalent, or trivalent anions as counter ions and can be used for treating or preventing dyslipidemia (such as hyperlipidemia), cholestasis, bile acid diarrhea, and other diseases.
Owner:WATERSTONE PHARMA (WUHAN) CO LTD

Reducing a pathological blood level of bile acids with a liposome suspension

PCT designated stageWO2026078188A1Peptide/protein ingredientsDigestive systemBlood levelCholeic Acid
The present disclosure provides a combination of a liposomal suspension, and of albumin, for use as bile acid sequestrants, wherein the use comprises (a) intraperitoneally administering the liposomal suspension to a subject in need thereof; and (b) intravenously or intraperitoneally administering the albumin to the subject; and (c) removing a dialysate containing liposomes and at least one bile acid from the subject, wherein the at least one bile acid comprises cholic acid, glycocholic acid, glycochenodeoxycholic acid or a combination of at least two thereof.
Owner:GENFIT SA